Modulation of matrix metalloproteinase activities in periodontitis as a treatment strategy.
Ryan
M E
ME
Department of Oral Biology and Pathology, School of Dental Medicine, State University of New York at Stony Brook, Stony Brook, New York, USA.
Golub
L M
LM
D016301:Alveolar Bone Loss / Q000188:drug therapy / Q000201:enzymology; D000818:Animals; D002614:Chelating Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004790:Enzyme Induction; D005109:Extracellular Matrix / Q000378:metabolism; D006801:Humans; D006877:Hydroxamic Acids / Q000627:therapeutic use; D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases / Q000378:metabolism*; D010518:Periodontitis / Q000188:drug therapy* / Q000201:enzymology*; D011480:Protease Inhibitors / Q000627:therapeutic use*; D013754:Tetracyclines / Q000627:therapeutic use; D015854:Up-Regulation
D002614:Chelating Agents; D006877:Hydroxamic Acids; D061965:Matrix Metalloproteinase Inhibitors; D011480:Protease Inhibitors; D013754:Tetracyclines; D020782:Matrix Metalloproteinases